Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NEU2 | Q9Y3R4 | 3/20 | 0.47 |
| ▸ | NEU4 | Q8WWR8 | 2/20 | 0.47 |
| ▸ | NEU3 | Q9UQ49 | 2/20 | 0.47 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.47 |
| ▸ | SELL | P14151 | 1/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | MAG | P20916 | 2/20 | 0.42 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20306037 | 1.00 | NANP (0.54) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL23635227 | 1.00 | NANP (0.54) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL13895438 | 1.00 | NANP (0.54) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL13895451 | 1.00 | NANP (0.54) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL23640238 | 1.00 | NANP (0.54) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL13896479 | 0.91 | L3MBTL1 (0.47) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL23640153 | 0.89 | L3MBTL1 (0.46) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL14275077 | 0.88 | NANP (0.53) | NANPNEU4NEU3NEU1 | |
| SCHEMBL15147281 | 0.88 | NANP (0.55) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL12109014 | 0.88 | NANP (0.53) | NANPNEU4NEU3NEU1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210875-A1 | LIPOSOMAL COMPOSITION FOR USE IN A METHOD OF TREATING PARKINSON'S DISEASE | INNOMEDICA HOLDING AG (CH) | 2023-07-06 | — | — | US | disclosed |
| US-20170321245-A1 | Flash and Glow 1,2-Dioxetanes | Life Technologies Corporation | 2017-11-09 | — | — | US | disclosed |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| EP-2590958-B1 | IN SITU CHEMILUMINESCENT SUBSTRATES AND ASSAYS | LIFE TECHNOLOGIES CORP (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140154675-A1 | Flash and Glow 1,2-Dioxetanes | Life Technologies Corporation (US) | 2014-06-05 | — | — | US | disclosed |
| US-RE44778-E1 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-RE44778-E1 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-7989601-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100204170-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100204170-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-7728117-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728117-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090036386-A1 | Heterobifunctional compounds for selectin inhibition | GLYCOMIMETICS, INC (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036386-A1 | Heterobifunctional compounds for selectin inhibition | GLYCOMIMETICS, INC (US) | 2009-02-05 | — | — | US | disclosed |
| US-20070105755-A1 | One pot desialylation and glycopegylation of therapeutic peptides | NEOSE TECHNOLOGIES, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | GLYCOMIMETICS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | GLYCOMIMETICS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170321245-A1 | Flash and Glow 1,2-Dioxetanes | GLO1, DDX41, GDA | NANP 1918/4885L3MBTL1 3591/4885NEU2 3593/4885 |
| US-20090036386-A1 | Heterobifunctional compounds for selectin inhibition | SELE, SELL, BSG | NANP 999/4885L3MBTL1 2197/4885NEU2 29/4885 |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | NANP 776/4885L3MBTL1 2309/4885NEU2 24/4885 |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | BSG, SELE, SELL | NANP 3180/4885L3MBTL1 550/4885NEU2 483/4885 |
| US-20070105755-A1 | One pot desialylation and glycopegylation of therapeutic peptides | UGGT1, PTMS, GALNT1 | NANP 832/4885L3MBTL1 1265/4885NEU2 49/4885 |
| US-20100204170-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | NANP 776/4885L3MBTL1 2309/4885NEU2 24/4885 |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | NANP 776/4885L3MBTL1 2309/4885NEU2 24/4885 |
| US-20230210875-A1 | LIPOSOMAL COMPOSITION FOR USE IN A METHOD OF TREATING PARKINSON'S DISEASE | GBA1, GALC, SMPD3 | NANP 381/4885L3MBTL1 2530/4885NEU2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.